Is Canopy Growth Stock Finally Worth Buying After Losing 99% of Its Value?

Canopy Growth’s fiscal 2026 revenue rose 6% to $200.4M (cannabis revenue +15%) and net cash improved to $92M, but the company remains unprofitable with negative free cash flow. The article flags execution and policy risk: the investment case still depends on cannabis reform and achieving positive adjusted EBITDA during fiscal 2027. Dilution risk persists given prior share issuances, so progress is viewed as encouraging rather than a definitive buy signal.

Analysis

CGC’s improved liquidity lowers near-term default/dilution risk, but that matters more for creditors and counterparties than for equity unless it converts into sustained free cash flow. In cannabis, survival capital often just extends the runway for low-return competition; that can actually keep industry pricing pressure alive longer by preventing the clean exits that would normally support margins.

The stock’s rerating hinge is not revenue growth in isolation but whether operating leverage shows up before the cash buffer is consumed. Over the next 1-3 quarters, the key falsifier is any re-acceleration in cash burn or a reset to financing language; that would quickly pull dilution back into the model and cap the multiple. If management merely stays within a narrow EBITDA improvement band, the equity remains a trading vehicle, not an investment case.

Contrarian view: the market may be overpricing the strategic value of balance-sheet repair and underpricing the second-order effect that a stronger CGC can keep Canadian cannabis promotion intensity elevated, pressuring peers like TLRY, SNDL, and OGI. Six to eighteen months out, the real upside catalyst is still regulatory: without a clearer legal/tax inflection, the sector’s cost of capital stays too high for durable equity compounding. That makes this more of an avoid/bearish relative-value setup than a standalone long, unless there is verifiable FCF inflection.

Key Decisions for Investors

• Avoid initiating a long CGC position here; wait for at least 2 consecutive quarters of positive operating cash flow or a clear guide-to-free-cash-flow inflection. Until then, the expected value is dominated by dilution risk, not growth optionality.
• Relative-value: consider long CRON / short CGC over a 3-6 month horizon if you want cannabis exposure. The cleaner capital structure and lower financing overhang should command a higher quality multiple if sector sentiment stabilizes.
• If CGC rallies sharply on turnaround headlines, use that strength to buy 3-6 month put spreads rather than outright shorts. Risk/reward improves because the core thesis is not bankruptcy but repeated equity issuance and multiple compression on missed cash-flow milestones.
• Set an alert for any management commentary on financing, covenants, or cash burn. A return to capital-raise language would be the clearest catalyst to press bearish exposure; absent that, the stock can drift without a tradable edge.